Home > Cardiology > EHRA 2022 > Letter from the Editor

Letter from the Editor

Editor
Prof. Michiel Rienstra, University Medical Center Groningen, the Netherlands
Conference
EHRA 2022
orig text:

Dear Colleagues, We thank you for your interest in this summary report for the 2022 European Heart Rhythm Association Meeting in Copenhagen, Denmark. It was an exciting return to meet face-to-face again after the pandemic years, and learning, sharing and networking together in-person. Our editorial team and peer reviewers have worked hard to bring you some of the very best content of the meeting. You will find late-breaking science, new evidence and updates on the following topics: Diagnostics and Prevention, Developments in Devices, Updates on Ablation, News on Atrial Fibrillation, and Other topics. Conduction system pacing and Pulsed field ablation were the new technologies that gained lots of atttention. Techniques in the centre of attention were artificial intelligence, remote monitoring, and screening. And last but not least, better patient characterisation and selection were key topics in numerous scientific sessions. We hope you find our peer-reviewed summaries informative, balanced, and of help in your clinical practice. Sincerely, Michiel Rienstra
Biography Michiel Rienstra, MD, PhD, MHA, is Cardiologist and Professor of Clinical Cardiology and serves as Clinical Director of the Department of Cardiology, and cardiologist at the University Medical Center Groningen, The Netherlands. He is founder of the regional network HeartNet Northern-Netherlands. Prof. Rienstra earned his medical degree at the University of Antwerp, Belgium, his PhD degree at the University of Groningen, the Netherlands, and his Master of Health Administration at Tilburg University, the Netherlands. He combines treatment of patients with arrhythmias and HF with clinic-oriented AF and HF research. His research consists of conducting investigatorinitiated clinical studies to improve AF or HF treatment (among others the RACE study group) studying the epidemiology of AF and its risk factors, uncovering the genetics of AF in part with the AFGen international consortium, and applying novel bioinformatics tools to improve AF risk prediction using biobanks of AF patients. He is fellow of the European Society of Cardiology and the American Heart Association. Research: Orchid: 0000-0002-2581-070X, publications: https://pubmed.ncbi.nlm.nih.gov Website: www.groningencardiology.com Email: m.rienstra@umcg.nl
Conflict of interest statement: Consultancy fees from Medtronic, Arca Biopharma Inc, and Roche to the institution.


parsed elements:




Source with stripped tags:

Dear Colleagues, We thank you for your interest in this summary report for the 2022 European Heart Rhythm Association Meeting in Copenhagen, Denmark. It was an exciting return to meet face-to-face again after the pandemic years, and learning, sharing and networking together in-person. Our editorial team and peer reviewers have worked hard to bring you some of the very best content of the meeting. You will find late-breaking science, new evidence and updates on the following topics: Diagnostics and Prevention, Developments in Devices, Updates on Ablation, News on Atrial Fibrillation, and Other topics. Conduction system pacing and Pulsed field ablation were the new technologies that gained lots of atttention. Techniques in the centre of attention were artificial intelligence, remote monitoring, and screening. And last but not least, better patient characterisation and selection were key topics in numerous scientific sessions. We hope you find our peer-reviewed summaries informative, balanced, and of help in your clinical practice. Sincerely, Michiel Rienstra
Biography Michiel Rienstra, MD, PhD, MHA, is Cardiologist and Professor of Clinical Cardiology and serves as Clinical Director of the Department of Cardiology, and cardiologist at the University Medical Center Groningen, The Netherlands. He is founder of the regional network HeartNet Northern-Netherlands. Prof. Rienstra earned his medical degree at the University of Antwerp, Belgium, his PhD degree at the University of Groningen, the Netherlands, and his Master of Health Administration at Tilburg University, the Netherlands. He combines treatment of patients with arrhythmias and HF with clinic-oriented AF and HF research. His research consists of conducting investigatorinitiated clinical studies to improve AF or HF treatment (among others the RACE study group) studying the epidemiology of AF and its risk factors, uncovering the genetics of AF in part with the AFGen international consortium, and applying novel bioinformatics tools to improve AF risk prediction using biobanks of AF patients. He is fellow of the European Society of Cardiology and the American Heart Association. Research: Orchid: 0000-0002-2581-070X, publications: https://pubmed.ncbi.nlm.nih.gov Website: www.groningencardiology.com Email: m.rienstra@umcg.nl
Conflict of interest statement: Consultancy fees from Medtronic, Arca Biopharma Inc, and Roche to the institution.


Posted on